Tuesday, 26 November 2024
  
Login

Australia's most trusted
source of pharma news

Tuesday, 26 November 2024
News

MSAC says it won't jump the gun

Posted 25 November 2024 AM

There's a lot on the line for Servier in the PBAC's pending November meeting outcomes after MSAC deferred a codependent submission regarding its bile duct cancer treatment Tibsovo.

Tibsovo is an oral, potent, and reversible selective inhibitor of the IDH1 mutant protein, making it a highly targeted therapeutic candidate for treatment patients with cholangiocarcinoma that harbours an IDH1 mutation.

To see the whole article, please login

Popular

2024's last PBS listing hopefuls
Patients pick best pharma
Sanofi request sparks new warning
Top pharmas for women revealed
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home